Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy by Singh, Naveen et al.
cancers
Review
Therapeutic Strategies and Biomarkers to Modulate
PARP Activity for Targeted Cancer Therapy
Naveen Singh 1 , S. Louise Pay 1, Snehal B. Bhandare 1, Udhaya Arimpur 1 and
Edward A. Motea 1,2,*
1 School of Medicine, Department of Biochemistry and Molecular Biology, Indiana University,
Indianapolis, IN 46202, USA; navsing@iu.edu (N.S.); slpay@iupui.edu (S.L.P); snebhan@iu.edu (S.B.B.);
uarimpur@iu.edu (U.A.)
2 Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN 46202, USA
* Correspondence: eamotea@iu.edu
Received: 18 February 2020; Accepted: 7 April 2020; Published: 14 April 2020


Abstract: Poly-(ADP-ribose) polymerase 1 (PARP1) is commonly known for its vital role in DNA
damage response and repair. However, its enzymatic activity has been linked to a plethora of
physiological and pathophysiological transactions ranging from cellular proliferation, survival
and death. For instance, malignancies with BRCA1/2 mutations heavily rely on PARP activity for
survival. Thus, the use of PARP inhibitors is a well-established intervention in these types of tumors.
However, recent studies indicate that the therapeutic potential of attenuating PARP1 activity in
recalcitrant tumors, especially where PARP1 is aberrantly overexpressed and hyperactivated, may
extend its therapeutic utility in wider cancer types beyond BRCA-deficiency. Here, we discuss
treatment strategies to expand the tumor-selective therapeutic application of PARP inhibitors and
novel approaches with predictive biomarkers to perturb NAD+ levels and hyperPARylation that
inactivate PARP in recalcitrant tumors. We also provide an overview of genetic alterations that
transform non-BRCA mutant cancers to a state of “BRCAness” as potential biomarkers for synthetic
lethality with PARP inhibitors. Finally, we discuss a paradigm shift for the use of novel PARP
inhibitors outside of cancer treatment, where it has the potential to rescue normal cells from severe
oxidative damage during ischemia-reperfusion injury induced by surgery and radiotherapy.
Keywords: PARP Inhibitors; beta-lapachone; NQO1; PARG; NAMPT; cancer therapeutics; DNA
repair; cMET
1. Introduction
Maintenance of genomic integrity is vital to achieve normal cellular function and to prevent the
development of diseases such as cancer [1]. At the heart of this intricate biological process are DNA
repair factors that work harmoniously to scan, detect, and repair potentially deleterious damage to
cellular genetic information. Indeed, the disruption of one or more DNA repair pathways compromises
genetic stability and is a known mechanism of cancer initiation, development, and progression.
Poly-(ADP-ribose) polymerase 1 (PARP1) is the classical and founding member of at least 17 human
PARP enzymes that share the ability to catalyze the transfer of ADP-ribose units to target proteins
to modulate chromatin structure, transcription, replication, DNA damage response and repair [2].
PARP1 is an abundant nuclear protein that acts as a DNA damage sensor and a facilitator of DNA
repair pathway choice in response to cellular stress [3–6]. Specifically, it is involved in the repair of
single-stranded DNA breaks (SSB) via the base-excision repair (BER) pathway. In BER, PARP1 functions
to recruit other repair factors by binding to single-stranded DNA break intermediates. Additionally,
it catalyzes the synthesis of poly(ADP)-ribose (PAR) chains to the acceptor proteins (e.g., histones and
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XRCC1), including itself, using nicotinamide adenine dinucleotide (NAD+) as the substrate and source
of energy. The PARylated proteins then recruit and retain critical processing factors to the site of the
lesion to facilitate the efficient repair of the SSB (Figure 1A) [7].
Figure 1. The role of PARP1 in DNA damage response and repair and cancer therapy. (A) PARP1 binds
to single-strand breaks (SSB) for activity to target, recruit and retain critical DNA repair proteins at the
sites of DNA lesions. (B) PARP inhibitors convert SSBs to lethal double-stranded breaks (DSBs) that are
left unrepaired in BRCA-deficient cells due to a compromised homologous recombination (HR) repair
consequently leading to cell death.
In the absence of PARP1, unrepaired SSBs are converted to double-stranded breaks (DSBs) during
replication or the S-phase of the cell cycle [8]. Double-stranded DNA breaks are one of the most
lethal forms of DNA damage induced by exogenous DNA damaging agents (e.g., ionizing radiation
(IR) and chemotherapeutic agents) or endogenous replicative stress in fast proliferating cancer cells.
Thus, accurate repair of DSBs is paramount to the growth and survival of all cells. Indeed, cells
have evolved a range of DSB repair mechanisms. The two major repair pathways that have been
studied extensively are homologous recombination (HR) and non-homologous end-joining (NHEJ) [9].
HR is largely error-free and more prevalently activated during and after DNA duplication when
an identical chromatid is accessible as a template for repair. In contrast, NHEJ is active throughout
the cell cycle and promotes direct ligation of DSB ends at the cost of small insertions, deletions,
substitutions at the break, and even translocations that arise if DSBs from different parts of the genome
are combined [10]. Cells utilize two mechanistically distinct end-joining pathways to process DNA
DSBs [10–12]: Classical-NHEJ (c-NHEJ) leads to a minimal sequence alteration at the repair junctions,
whereas alternative-NHEJ (alt-NHEJ, also known as microhomology-mediated end-joining (MMEJ) or
back-up NHEJ) causes extensive genetic changes (deletions and insertions) that scar the break sites
following ligation of DSB ends.
Several studies have shown that loss-of-function mutation of canonical HR factors – such as
breast cancer type 1 and 2 (BRCA1/2) susceptibility proteins that are commonly associated with breast
and ovarian cancer [13–15] – promotes PARP1 hyperactivation in fast replicating cancer cells [16,17].
This suggests that hyperactivation of PARP1 is essential to facilitate the repair of potentially lethal
DNA breaks for the survival of HR-defective (HRD) cancers. Indeed, BRCA1/2 mutant cancers are
selectively killed by PARP inhibitors (Figure 1B), which has led to the approval of these agents to treat
HR-deficient ovarian and breast cancers. However, several studies have reported that certain cancers
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without a BRCA deficiency have significant clinical benefits to PARP1 inhibitors positing that PARP
inhibitors could be expanded to a target population beyond BRCA-deficiency (e.g., gBRCA mutation
carriers) [18–21].
This review article highlights treatment strategies to selectively target BRCA-proficient cancers by
modulating PARP activity that alters PARP binding, PAR and NAD+ levels to induce tumor-selective cell
death using predictive biomarkers for therapeutic response. We summarize how aberrant alterations of
PARG, NAMPT, NQO1, cMET and “BRCAness” genes that have been shown to affect PARP activity in
cancers could serve as prognostic biomarkers for targeted therapy. Finally, we briefly discuss innovative
approaches for the use of novel PARP inhibitors to rescue injured normal cells from severe oxidative
damage during ischemia-reperfusion injury that could be induced by surgery and radiotherapy.
2. Mechanism of Action for PARP Inhibitors
PARP inhibitors are designed to mimic the substrate-protein interactions of NAD+ within the
ADP-ribose transferase (ART) catalytic core of PARP1-3, which are key DNA damage response
sensors and transducers. The inhibitors compete with NAD+ binding site of PARP to inhibit PAR
polymerization, which then hinders the recruitment and regulation of DNA repair factors and the
eventual release of PARP from DNA damage. Two mechanisms are proposed to induce the lethality
of PARP inhibitors: PARP catalytic inhibition and PARP trapping [22,23]. However, the relative
contributions of these two pathways in mediating the lethality of PARP inhibitors remain enigmatic.
For example, there is evidence suggesting that the differences in the trapping potential of PARP1 to
the DNA are more efficient at killing HR-deficient cells [22,23]. While there has been no evidence
that this mechanism exists with clinically-used PARP inhibitors, a recent study has demonstrated
that certain non-hydrolysable NAD+ analogs (e.g., benzamide adenine dinucleotide, BAD) binding
at the catalytic site of PARP1 could greatly enhance the binding affinity of PARP1 at sites of DNA
damage that prevents its release [24]. Mechanistically, this analog competes with NAD+ at the catalytic
binding site that then stabilizes a conformation that induces the DNA binding domain of PARP1 to
be locked on a DNA break with a significantly better binding affinity (~10-fold) – a phenomenon
known as “reverse allostery.” While most PARP inhibitors (e.g., Rucaparib) bind at the catalytic site,
not all of them are “created equal.” In fact, the relative contribution of DNA trapping induced by PARP
inhibitors contributes significantly to the toxicity induced by these agents in cancers that are deficient
in HR pathways [23,25–27]. Some of them have variable inhibitory effects on the PARP isoforms
other than PARP1, and some may have more off-target effects on kinases than others. Regardless,
PARP inhibitors are now being explored for use in several cancers, even in cancers beyond BRCA
mutations [25,28–30]. Interestingly, a recent study has reported a correlation between therapeutic
response to PARP inhibition and the patterns of ADP-ribosylation (i.e., amount of PARylation) in a
panel of ovarian cancers, suggesting that ADP-ribosylation may be a useful biomarker for HR deficiency
and sensitivity to PARP inhibitors regardless of BRCA status [31]. While most of the PARP inhibitors
have been suggested to specifically inhibit PARP1 and/or PARP2, our limited understanding of the
overlapping and non-overlapping functions and cross-talks among all of the PARP family members still
raises the problem of target specificity and the risk of unintended effects and consequences promoted
by the targeting of other PARP family members.
3. Approved PARP Inhibitors for Targeted Cancer Therapy
PARP inhibitors such as Olaparib [32,33], Rucaparib [34], and Niraparib [35] have been approved
by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for the
treatment of adults with deleterious or suspected deleterious germline BRCA-mutated ovarian cancer
in different settings [36]. Moreover, these agents have also been approved for maintenance therapy
in platinum-sensitive high-grade ovarian cancer (HGOC), which has a high recurrence rate and an
extremely poor prognosis following relapse [37]. Currently, PARP inhibitors are being evaluated in
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clinical trials in other cancer settings such as nonsmall cell lung cancer, pancreatic cancer, and gastric
cancer (ClinicalTrials.gov Identifiers NCT01082549, NCT02184195, NCT03427814, respectively).
Olaparib (LYNPARZA, AstraZeneca and Merck) was the first PARP inhibitor to receive FDA
approval for indications in breast cancer and pancreatic cancer, and has since been approved for
metastatic breast cancer in patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations. In 2009,
Olaparib was deemed safer than conventional chemotherapeutics, with mild and reversible side effects
during clinical trials [26]. It was subsequently determined to have anti-tumor activity in advanced
ovarian cancer patients with gBRCA1/2 mutations, particularly with primary tumors that are sensitive
to platinum [18,32,38–40]. The phase III OlympiAD trial found a 60% reduction in metastatic BRCA1/2
mutant breast tumor size with Olaparib in comparison to 29% in patients receiving conventional
chemotherapy. The FDA approved Olaparib in ovarian and breast patients with gBRCA mutations in
2014 and 2018, respectively [27,41–43].
Rucaparib (RUBRACA, Clovis Oncology, Inc.) was granted accelerated approval by the FDA in
2016 for the treatment of adult ovarian cancer patients with germline and/or somatic BRCA-mutations
previously treated with two or more prior lines of chemotherapy. This agent is also approved as a
maintenance monotherapy for adult patients with recurrent ovarian cancer who have established
complete or partial response (CR/PR) to platinum-based chemotherapy. In 2018, Rucaparib gained
FDA approval for the maintenance treatment of advanced or recurrent ovarian, fallopian tube, and
primary peritoneal cancer in patients who have received platinum-based chemotherapies, as well
as in patients with germline or somatic BRCA1/2 mutations following two or more treatments with
conventional chemotherapy [44,45].
Niraparib (ZEJULA, Tesaro, Inc.) was approved by the FDA and EMA in 2017. Compared
to Olaparib, this agent results in longer progression-free survival in patients with BRCA1/2-mutant
tumors [35]. Niraparib also increases progression-free survival in patients with wild-type BRCA1/2
ovarian cancers, though less effectively than in patients with BRCA mutations [35]. Niraparib, however,
is associated with more severe side effects than other PARP inhibitors, with patients experiencing
thrombocytopenia (33.8%), anemia (25.3%), and neutropenia (19.6%) [35]. In 2019, the FDA approved
Niraparib for homologous recombination-deficient (HRD) patients with advanced ovarian, fallopian
tube, or primary peritoneal cancer previously treated with three or more chemotherapies [46].
Talazoparib (TALZENNA, Pfizer, Inc.) is a new active PARP inhibitor approved by the FDA
in 2018 for patients with deleterious or suspected deleterious gBRCA-mutated, HER2-negative local
advanced or metastatic breast cancer [47]. Compared to other PARP inhibitors, Talazoparib is still at
an early stage of clinical development in gathering evidence to support its use on the treatment of
epithelial ovarian cancer.
4. Harnessing the Power of PAR and PARG Inhibition for Cancer Therapy
Poly(ADP)-ribosylation (PARylation) is a covalent and reversible posttranslational modification
(PTM) of acceptor proteins catalyzed by PARPs, particularly in response to DNA damage and oxidative
stress [48,49]. PARylation is also a critical signaling PTM for other biological transactions such as
transcription, cell cycle regulation, and genome maintenance [50–52]. Intracellular PAR levels are very
low in unstressed cells due to low enzymatic activity of PARP. When PARP1 is activated following
DNA damage, PAR formation increases and consequently depletes intracellular NAD+ and ATP
levels [53]. Accumulation of PAR and loss of NAD+ and ATP can lead to severe metabolic dysfunction
and eventual cell death. Thus, the balance between ADP-ribose synthesis (i.e., PAR writers) and
degradation (i.e., PAR erasers) is critical for the coordination of various cellular response pathways for
survival [54].
Poly(ADP-ribose) glycohydrolase (PARG) is an endo- and exo-glycohydrolase that rapidly
catalyzes the degradation of PAR polymerized by PARP1 to coordinate DNA repair [48,49]. It is
comprised of an N-terminal regulatory domain required for recruitment to DNA damage sites [55],
a C-terminal catalytic domain, and a central mitochondrial-targeting sequence [56]. PARG hydrolyzes
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the glycosidic bonds between ADP-ribose units producing free ADP-ribose and PAR oligomers
(Figure 2A) [57], which play distinct biological roles in cellular processes. Free ADP-ribose is
predominantly involved in energy catabolism, calcium signaling, and protein glycation [57]. The
long-chain of free PAR formed by PARG cleavage has been shown to interact with the mitochondrial
proteins triggering a unique intrinsic PAR-mediated cell death program known as PARthanatos
(Figure 2A) [58,59]. Mechanistically, a cell commits to PARthanatos when free PAR (> 60 ADP-ribose
units) migrates from the nucleus to the cytosol, which then triggers the translocation of PAR-bound
apoptosis-inducing factor (AIF) from the mitochondria to the nucleus to activate the cell death
process (Figure 2A) [60]. Early events in PAR-mediated cell death include loss of mitochondrial
membrane potential and mitochondrial permeability transition [61]. While caspase activation has been
demonstrated to act as a bystander in PAR-dependent cell death, this caspase-independent process
shares cytological and morphological characteristics of both necrosis and apoptosis [58,59].
Figure 2. Pharmacological modulation of PAR ad NAD+ in cancers for therapy. (A) Mechanism
of PARthanatos mediated by the translocation of cleaved PAR from the nucleus to the cytosol and
mitochondria to induce the release of AIF that translocates into the nucleus to initiate death in
PARG-overexpressing cancers. Alternatively, breakdown and recycling of PAR can be prevented by
inhibition of PARG to enhance NAD+ depletion caused by PARP hyperactivation, ultimately starving
the cell of ATP needed for various critical cellular processes (e.g., DNA repair). (B) In cancer cells that
overexpress NAMPT, the use of NAMPT inhibitors interfere with generation of intracellular NAD+
levels that compromise PARP activity, consequently resulting in impaired repair of DNA damage and
NAD+-Keresis.
ADP-ribose hydrolases (ARH) can catalyze PAR hydrolysis but to a lesser extent than PARG,
which catalyzes the majority (~90%) of PAR catabolism [62]. PARG is aberrantly overexpressed in
most human cancers, suggesting that PARG is required for tumorigenesis and cancer survival [63].
Therefore, inducing cell death via PARG inhibition and manipulation of the PAR cycle through
PARP1/PARG inhibition is an attractive target for cancer therapy (Figure 2). Available PARG
inhibitors consist of DNA intercalators, tannins, and substrate analogs. DNA intercalators (e.g.,
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Tilorene, GPI116552, GPI18214, Ethacridine) indirectly inhibit PARG by forming complexes with its
substrate, PAR [64–66]. Hydrolyzable tannins (e.g., Nobotanin B, Oenothenin B, gallotannin) inhibit
PARG in vitro by competing with the PAR substrate [67–69]; however, poor membrane permeability,
poor bioavailability, and toxicity of these compounds hinder their usage. Adenosinediphosphate
(hydroxymethyl) pyrrolidinediol (ADP-HPD), a nonhydrolyzable-analogue of ADP-ribose, has been
shown to be a potent competitive PARG inhibitor [66]. Other reversible PARG inhibitors under
development include modified salicylanilide pharmacophore [70] and rhodanine-based small molecule
analogs (RBPIs) [70]. Recently, Pillay et al. [71] demonstrated that PARG inhibitor, PDD00017273,
mimics poly(ADP-ribose) polymerase (PARP) inhibitor therapy in ovarian cancer cells by exacerbating
the formation of hyperPARylated-PARP1 that severely compromises PARP activity. Mechanistically,
PARG inhibitors prevent the recycling of hyperPARylated-PARP1 to its more active form for efficient
DNA damage response and repair. In support of this, survival studies of certain human cancer cell
lines with PARG knockdown synergistically enhances the lethality to DNA-damaging agents such as
alkylating agents [72,73] and cisplatin [72]. Overall, pharmacological targeting of PARG is a promising
therapeutic target and future investigations are required to develop effective strategies to manipulate
the dynamic PAR formation and break-down process in response to DNA damage. The relative low
abundance of PARG in normal cells, compared to tumors with aberrant PARG overexpression, makes
it an attractive target in cancer therapeutics for tumor-selective drug response. Moreover, unlike
the human PARP family with 17 related enzymes with almost similar catalytic subunit – PARG is
a unique mammalian protein without any paralogs, which may offer fewer off-target effects than
PARP inhibitors.
5. Targeting NAD+ for Cancer Therapy
NAD+ is a co-enzyme that mediates redox reactions by acting as an electron carrier and a
substrate in metabolic pathways including glycolysis, the tricarboxylic acid cycle (TCA), oxidative
phosphorylation, and serine biosynthesis [74]. It is a cofactor for PARP and plays a key role
in energy production, cell signaling, redox homeostasis, DNA repair, gene expression, and the
stress response. Many of these processes are disrupted in cancer, which alters NAD+ production
and consumption [75,76]. Nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide
mononucleotide adenylyltransferase (NMNAT) enzymes regulate the salvage pathway critical for
controlling intracellular NAD+ levels [77]. Increased NAD+ and aberrant NAMPT overexpression
promotes glycolysis, which fuels the growth and survival of cancer cells [78,79]. Indeed, NAMPT
inhibitors suppress cancer cell proliferation by inhibiting glycolysis [79–83].
Overexpression of NAMPT is observed in several types of malignant tumors, which supplies
back-up NAD+ to sustain cellular proliferation and promote resistance to therapeutic agents [84–89].
NAMPT as a predictive biomarker for tumor-selective targeting of NAD+ metabolism is, therefore, a
promising therapeutic strategy (Figure 2B). Mechanistically, NAMPT inhibitors induce cell death in
cancer cells by depleting intracellular NAD+ and ATP levels and inhibiting glycolysis and glucose
uptake [90,91]. Examples of NAMPT inhibitors include FK866, GMX-1777/8, STF-31, STF-118804,
GNE-617, GNE-618, LSN3154567, KPT-9274. Vacor adenine dinucleotide (VAD) is an NAD+ analog
that has been shown to inhibit both NAMPT and NMNAT, leading to necrotic cell death through NAD+
depletion (NAD+-Keresis, Figure 2B), glycolytic block, and energy failure [82,92–98]. Several NAMPT
inhibitors have been investigated in the clinic as a monotherapy such as FK866 and GMX-1777/8.
However, thrombocytopenia was demonstrated to be the dose-limiting toxicity in these clinical
trials [99,100]. Though NAMPT inhibitors as a monotherapy are promising candidates for cancer
therapy, drug resistance and toxicity to normal tissues when used at high concentration remain a major
hurdle [99,101–103]. Perhaps, a combination approach with tumor-selective DNA damaging agents
(e.g., NQO1-bioactivatable agents, vide infra in Section 6) may overcome this limitation to improve the
tumor-selectivity of NAMPT inhibitors by severely depleting the NAD+ needed by PARPs for efficient
DNA repair and survival [82,104].
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6. Leveraging NQO1 as a Biomarker for Tumor-Selective Use of PARP Inhibitors with
NQO1-Bioactivatable Drugs
NAD(P)H:Quinone Oxidoreductase 1 (NQO1, DT-diaphorase) is a cytoplasmic Phase II
detoxification enzyme that utilizes NAD(P)H to reduce certain quinones to stable hydroquinones
via two-electron reductions that are readily conjugated by Phase III transporters for cellular efflux
(Figure 3A) [105]. NQO1 is abnormally overexpressed in most malignant tumors, which contributes
to drug resistance by metabolizing xenobiotics to their inactive forms or chemical structures that
are excreted out of the cell for chemoprotection. Indeed, the addition of an NQO1-inhibitor (e.g.,
dicoumarol) in cancers could sensitize the anti-cancer effects of certain agents by inhibiting resistance
due to drug efflux.
Figure 3. Strategy for tumor-selective use of PARP inhibitors in solid tumors. (A) The role of NQO1 in
detoxifying certain quinones for cellular efflux. (B) The role of NQO1 in bioactivating certain quinones
to induce toxicity in NQO1(+) cancer cells. Note that the stability of hydroquinones determine whether
bioreduction by NQO1 leads to detoxification or toxicity. (C) Mechanism of tumor-selective synergistic
cell death induced by combination of PARP inhibitor and NQO1-bioactivatable agents in NQO1(+) cells.
Certain quinones are bioactivated by NQO1 to create a rapid increase in reactive oxygen species
(ROS), particularly hydrogen peroxide (H2O2), which can permeate through the nucleus to induce the
formation of toxic DNA damage leading to cell death (Figure 3B) [106–110]. For example, β-lapachone
(β-lap) is a soluble ortho-naphthoquinone with potent anti-tumor and radiosensitizing activity only in
the presence of high NQO1 activity [108–114], which is only noted in most malignant tumors but not
in normal tissues [109]. Mechanistically, the two-electron reductase capacity of NQO1 catalyzes the
oxidoreduction of β-lap to an inherently unstable hydroquinone, which automatically and rapidly gets
reverted back to its original quinone form as it undergoes a two-step oxidation (Figure 3B) [108]. This
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produces what is termed as a “futile cycle” of oxidation and produces a significant level of reactive
oxygen species such as superoxide radicals (O2−) that are rapidly catalyzed by superoxide dismutases
to hydrogen peroxide in the cytoplasm (Figure 3B) [115]. This stable form of ROS can easily penetrate
through the nucleus and is converted to genotoxic hydroxyl radicals via the Fenton reaction process,
which causes massive formation of oxidative DNA base damage and SSBs (Figure 3B) [109,116]. The
surge of this specific types of DNA damage in the nucleus causes hyperactivation of PARP1, which is
an NAD+-dependent enzyme, to a level that consequently leads to NAD+-Keresis death due to the
depletion of critical biological energy sources, NAD+ and ATP [82,107,109]. Another possibility is that
PARP hyperactivation could lead to an NAD+-independent glycolytic and bioenergetics crisis that
is presumably caused by PAR-dependent inhibition of glycolysis that occurs through the inhibition
of hexokinase leading to a specific form of cell death termed “PARthanathos” [117]. Future studies
are required to firmly establish the contribution of PARP hyperactivation, NAD+, or free PAR in
specific types of cell death. Regardless, the use of NQO1-bioactivatable agents to modulate PARP
activity, NAD+ and PAR to induce cell death is a viable strategy to treat cancer. As NQO1 is typically
overexpressed in tumors but not at a significant level in normal healthy cells [109], the application of
NQO1-bioactivatable agents is an attractive possibility for tumor-selective generation of H2O2-induced
DNA damages that hyperactivate PARP and deplete NAD+ to cause eventual cell death, which is vital
for developing safe and effective drugs with minimal off-target effects.
While β-lap (ARQ761 in clinical form) shows potential as a single-agent therapeutic [107,118], it
has also been associated with hemolytic anemia at a dose of 450 mg/m2 [119]. Therefore, increasing its
efficacy at a lower dose is therapeutically advantageous. Due to the role of PARP hyperactivation in the
mechanism of action of β-lap, PARP inhibitors have been a central focus in improving the efficacy and
reducing the toxicity of β-lap for use in NQO1(+) cancers. PARP inhibition followed by β-lap treatment
alters the mechanism of β-lap function by blocking the repair of damaged DNA and inhibiting PARP1
hyperactivation, slowing down the process of NAD+ depletion as a result, and extending the cycling
of β-lap by NQO1 to maximize hydrogen peroxide production and amplifying DNA damage in a
tumor-selective manner (Figure 3C) [109]. Instead of dying by caspase-independent NAD+-Keresis,
cell death from exposure to β-lap following PARP1 inhibition occurs through caspase-dependent
apoptosis, presumably due to the availability of NAD+ and ATP (Figure 3C) [109]. As NQO1 will
continue cycling β-lap until the drug is depleted or the required source of NAD(P)H is depleted,
blocking the DNA repair process which leads to NAD+ depletion following β-lap treatment prolongs
the efficacy of the drug, allowing for lower doses to be used with the synergistic effect, minimizing the
potential for hemolytic anemia.
The use of NQO1-bioactivatable drug (e.g., β-lap) with PARP inhibitors have been shown to
significantly expand the clinical application of PARP inhibitors outside of BRCA1/2 mutant cancers for
which the majority of PARP inhibitors are currently approved. The prevalence of NQO1 overexpression
in such a wide variety of malignant cancers (>90% in pancreatic cancers with KRAS mutation, >80%
nonsmall cell lung cancer (NSCLC), >60% breast cancer, >60% prostate cancer, >45% head and neck,
and >60% colon cancers [109]) suggests that this combination therapy may have significant future
potential, especially in cancers in which prognosis is currently poor, such as head and neck cancer,
pancreatic cancer and NSCLC [117,120–126].
7. Targeting cMET to Attenuate PARP1 Activity
Many studies have shown that most malignant tumors have increased levels of reactive oxygen
species (ROS), particularly hydrogen peroxide (H2O2), compared to their normal counterparts. These
genotoxic reactive species cause oxidative DNA damage and single-stranded DNA breaks that stimulate
PARP activity in DNA repair [127]. Interestingly, Du and colleagues [128] have shown that cMET,
which is a receptor tyrosine kinase, can further stimulate the activity of PARP1 in cancers to survive
the lethal effects of ROS-induced DNA damage. In cancer, cMET is overexpressed and its abnormal
activation can promote the development and progression of multiple cancers [129].
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Mechanistically, the high level of ROS in cancer promotes the activation and translocation of
cMET into the nucleus where it directly binds and phosphorylates the tyrosine residue 907 (Y907)
of PARP1 to enhance its enzymatic activity (Figure 4A) [128,130,131]. Indeed, Du and colleagues
have demonstrated that phosphorylated PARP1 (pY907) showed a higher level of PAR production
than non-phosphorylated PARP1 in vitro, thereby highlighting the critical role of cMET in enhancing
PARP1 activity in DNA repair [128,130,131]. Moreover, the phosphorylation of this specific residue
(pY907) has been suggested to significantly decrease the binding of clinically-relevant PARP inhibitors
due to a potential steric hindrance (Figure 4B) [128]. Indeed, c-MET-mediated phosphorylation
of PARP1 at Y907 leads to PARP inhibitor resistance, which could be potentiated when combined
with cMET inhibitors (e.g., crizotinib and foretinib) [128]. Thus, inhibition of cMET is an attractive
strategy to indirectly block PARP1-mediated DNA repair and enhance the therapeutic effects of PARP
inhibitors in cancer cells [128]. However, the mechanistic basis for requiring Y907 phosphorylation to
promote H2O2-induced PARP1 activity remains to be firmly established. A recent report also suggests
that phosphorylation of PARP1 by EGFR and cMET heterodimer contributes to PARP1 inhibitor
resistance. Hence, combination treatment consisting of EGFR, cMET, and PARP1 inhibitors posits a
novel therapeutic strategy in cancer treatment involving overexpression of PARP1/EGFR/cMET, which
are frequent alterations in most solid tumors [132].
Figure 4. Attenuation of PARP Activity by cMET inhibition. (A) cMET enhances PARP activity during
oxidative stress. Inhibition of cMET is an excellent strategy for inhibiting PARP1-mediated DNA
repair and synergy with PARP inhibitors. (B) A snapshot of non-hydrolyzable NAD+ analog (in cyan)
bound to residues in PARP1 catalytic active site within 6Å from the ligand (PDB ID: 6 bhv, processed
via PyMOL Molecular Graphics System). Phosphorylation of PARP1 residue Y907 (shown in green)
inhibits binding of PARP inhibitors.
8. Targeting of PARP Activity in Non-Oncological Events
PARP inhibition or gene deletion has been shown to attenuate tissue injury associated with
ischemia-reperfusion injury and inflammation that could arise during tumor surgical resection and
radiation therapy [133,134]. During this non-oncological event, the catalytic activity of PARP1 becomes
hyperactivated and consequently leads to NAD+ depletion. This process forces NAD+ replenishment
through the salvage pathway, which decreases cellular ATP levels and results in bioenergetic crisis,
eventually leading to necrotic cell death that is typically associated with inflammation [3,135]. Thus,
inhibition of PARP activity could have protective effects by dramatically reducing NAD+ consumption
and preventing energetic failure and the consequent necrotic cell death. While the trapping mechanism
induced by specific PARP inhibitors might be advantageous for the treatment of certain cancers, this
mechanism of action might not be optimal to rescue normal cells from severe oxidative damage during
ischemia-reperfusion injury (e.g., ischemia of the lung due to ionizing radiation [136] and cerebral
ischemia during surgery [137]).
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For non-oncological indications, the safety profile of most FDA-approved PARP inhibitors would
be expected to be better if it had less PARP trapping activity to restore the viability of normal tissue
damage from injury caused by ischemia-reperfusion. To circumvent the cytotoxic effects of PARP
trapping, the Yu group [138] developed a strategy to decrease PARP activity using a novel lead
compound, iRucaparib-AP6 (Figure 5), which promotes PARP degradation upon binding that mimics
PARP1 genetic deletion. Mechanistically, the Rucaparib component of the small molecule specifically
binds PARP at the site of damaged DNA, but it is attached to a linker with a ligand that brings the E3
ligase in close proximity to ubiquitinate PARP and subsequently gets degraded through the proteasome
pathway (Figure 5C). Unlike PARP trapping, this strategy of modulating PARP activity protects cells
against genotoxic stress-induced cell death [138] that could have potential clinical applications for
the treatment of ischemia-reperfusion injury and neurodegeneration. However, further development
is needed to firmly establish the mechanism of action and evaluate its protective effects to treat the
aforementioned non-oncological indications.
Figure 5. Development of a novel “PARP degrader” molecule as a biochemical probe and therapeutic
agent. (A) Chemical structure of Rucaparib. (B) Chemical structure and elements of iRucaparib-AP6.
(C) Simplified representation of the mechanism of action for a novel proteolysis targeting chimeric
(PROTAC) molecule, iRucaparib-AP6.
To summarize, the enzymatic function of PARP1 – which is to catalyze the PARylation of a
large number of PAR-acceptor proteins (including itself) – becomes hyperactivated upon detection of
genotoxic stresses associated with various pathological conditions such as cancer, ischemia-reperfusion
injury (e.g., myocardial infarction), inflammatory diseases (e.g., colitis, arthritis, asthma), vascular
diseases (e.g., diabetic complications, atherosclerosis), and neurodegeneration. Thus, modulation of
PARP activity using a novel class of PARP activity inhibitors (e.g., iRucaparib-AP6) with little to no
“trapping” potential may be a promising strategy to ameliorate certain pathological conditions that are
aimed to heal instead of killing the severely injured normal tissues (e.g., inflamed tissues). Indeed
several studies have looked at the protective effects of PARP inhibitors in lung transplantation [139],
neurodegeneration [140], renal injury [141], aging [142], and acute pancreatitis [143]. While these
studies offer critical insights toward the potential therapeutic repurposing of PARP inhibitors in treating
non-oncological indications, it is important to learn more about the possible side-effects of long-term
treatment and whether PARP inhibition may increase the risk of mutagenesis and carcinogenesis.
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9. Perspectives and Conclusions
Individualized treatments to patients with recalcitrant cancers in order to achieve cure are urgently
needed. Currently, cancer patients have many therapeutic options for treatment; however, the lack
of effective and tumor-selective treatment options still remains a major hurdle in the fight against
cancer today. This is due to very limited predictive biomarkers that define individual risks of disease
recurrence or sensitivity to treatments. For example, a significant number of cancer patients are
over-treated in order to possibly attain an improved overall survival in early cancer stage. This
“shotgun” approach, however, could have life-threatening consequences to cancer patients due to the
emergence of drug resistance and secondary malignancies. Clearly, there is an urgent need for (1) a
clear understanding of normal versus cancer cell biology to gain more informative decisions regarding
the most effective therapeutic interventions, and (2) an arsenal of new treatment options based on
predictive biomarkers for this disease to eliminate toxic effects to normal cells, drug resistance, and
development of secondary cancers.
In less than two decades, studies on the use of PARP inhibitors for the treatment of gBRCA1/2
mutant cancers and beyond BRCA-deficiency have increased tremendously. Of course, these were
all made possible by the collaborative effort of the scientific and medical communities to understand
the functional roles of breast cancer associated genes 1 and 2 (BRCA1/2) in normal physiology and
breast cancer development. Accordingly, deficiencies in BRCA1 and BRCA2 genes can compromise
HR-mediated repair, conferring hypersensitivity to PARP inhibitors by chemical synthetic lethality.
The rarity of breast (5–10%) and ovarian (15–20%) cancers with germline BRCA1/2 loss-of-function
mutations, however, currently restricts the therapeutic utility of PARP inhibitor monotherapy. This
is further complicated by several reports of potential molecular mechanisms of resistance for PARP
inhibitors in BRCA-deficient breast cancers [144]. Interestingly, approximately 24% of high-grade triple
negative breast cancers (TNBC) without a BRCA mutation showed great response to PARP inhibitor
in Phase II clinical trials suggesting that the use of PARP inhibitors can be expanded beyond BRCA
deficiency, and this has been reinforced by several studies in other cancers [18–21]. Indeed, genetic and
pharmacological alterations of specific proteins (Table 1) or long non-coding RNAs (lncRNAs, e.g.,
PCAT-1 [145]) that can induce a state of “BRCAness” or HR-deficiency in BRCA-proficient cancers have
the potential to broaden the application of PARP inhibitors beyond the current protocols approved by
the FDA and EMA.
In conclusion, a serious concern for the use of PARP inhibitors – as with all chemotherapeutic
agents – is the development of acquired drug resistance and de novo malignancies [146] due to limited
information and often unclear understanding of the full extent of the agents’ specificity and mechanism
of action. A complete and clear knowledge of how different PARPs are activated to perform overlapping
and non-overlapping functions or how PAR and NAD+ levels are modulated to alter specific biological
events toward cellular survival or death are essential to: (1) design novel PARP inhibitors that are more
specific and tumor-selective; (2) develop better mechanistic-based strategies using reliable predictive
biomarkers for PARP inhibitor monotherapy as well as combination treatments; and (3) identify
situations that can re-sensitize recalcitrant tumor cells to PARP activity inhibition or modulation to
treat cancer patients more safely and efficiently.
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Table 1. Representative list of genes/proteins that have been shown to cause “BRCAness” or HR defect
in BRCA-proficient tumors when expression is lost or activity is inhibited. These deficiencies could be
exploited as predictive biomarkers for precision treatment with PARP inhibitors.
Protein Name Primary Function/Activity Association with “BRCAness” Reference
CDK1 Cell cycle regulation
Loss of expression or activity
inhibition compromises
phosphorylation of BRCA1 for
proper HR function
[30]
CDK12/13 Phosphorylates RNAPII CTD
Loss of expression and activity
inhibition suppresses expression of
specific HR proteins such as RAD51
and BRCA1
[147]
AXL
A receptor tyrosine kinase
associated with metastasis,
invasion and migration in many
cancers
Loss of expression or activity
inhibition decreases expression of
specific HR genes and proteins
[148]
Kub5-Hera,
RPRD1B, CREPT Transcription termination factor
Loss of expression compromises HR
by decreasing CDK1 expression [25]
WEE1
Involved in the terminal
phosphorylation and inactivation
of CDK1-bound cyclin B
Activity inhibition with AZD1775
indirectly inhibits BRCA2 [149]
UCHL3 Deubiquitinase
Activity inhibition with perifosine
promotes ubiquitination of RAD51
and blocks the binding of RAD51
with BRCA2
[150]
BET Transcriptional regulators
Activity inhibition with JQ1
decreases expression of RAD51 and
Ku80
[151]
PI3K
Kinase involve in cell growth,
proliferation, differentiation,
motility, survival and intracellular
trafficking
Inhibition of activity impairs
BRCA1/2 expression [152]
Cyclin D1
Regulator of CDKs (cyclin
dependent kinases), required for
cell cycle G1/S transition
Loss of expression impairs
recruitment of RAD51 [153,154]
AURKA Play important role in mitosis/regulation of cell cycle progression
Activity inhibition or loss of
expression decreases expression of
BRCA1 and BRCA2
[155,156]
HKMT Regulation of histone methylation
Inhibition of activity abolishes
retention of BRCA1/BARD1
complexes at sites of DSB
[157,158]
CCDC6 Tumor suppressor
Loss of expression compromises
BRCC3 and DNA damage
checkpoints in response to DNA
damage.
[158,159]
MEK Kinase that phosphorylates andactivates MAPK
Activity inhibition or loss of
expression downregulates BRCA2 [160]
HDAC Removes acetyl groups from anamino acid on a histone
Activity inhibition with SAHA
reduces BRCA1 protein levels by
targeting the UHRF1/BRCA1
protein complex
[161]
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Table 1. Cont.
Protein Name Primary Function/Activity Association with “BRCAness” Reference
PAK1
Regulates cytoskeleton
remodeling, phenotypic signaling
and gene expression
Reduced activity and loss of
expression downregulates the
expression of genes involved in
FA/BRCA pathway
[162]
Androgen receptor DNA-binding transcription factorthat regulates gene expression
Activity inhibition or loss of
expression suppresses the
expression of HR genes, thus
creating HR deficiency and
BRCAness
[163]
TGFβ
Involved in embryonic
development, cell proliferation,
motility and apoptosis,
extracellular matrix production,
and immunomodulation
Overexpression suppresses BRCA1,
ATM, and MSH2 [164]
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